array:19 ["pii" => "13012061" "issn" => "02139111" "estado" => "S300" "fechaPublicacion" => "1999-08-01" "documento" => "article" "crossmark" => 0 "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Gac Sanit. 1999;13 Supl Congr 1:9053" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1801 "formatos" => array:3 [ "EPUB" => 190 "HTML" => 1364 "PDF" => 247 ] ] "itemSiguiente" => array:16 [ "pii" => "13012052" "issn" => "02139111" "estado" => "S300" "fechaPublicacion" => "1999-08-01" "documento" => "article" "crossmark" => 0 "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Gac Sanit. 1999;13 Supl Congr 1:9054" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2521 "formatos" => array:3 [ "EPUB" => 163 "HTML" => 2206 "PDF" => 152 ] ] "es" => array:6 [ "idiomaDefecto" => true "titulo" => "COSTE-EFECTIVIDAD DE LA VACUNACIÓN NEUMOCÓCICA" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "9054" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "D Vivas Consuelo" "autores" => array:1 [ 0 => array:2 [ "Iniciales" => "D" "apellidos" => "Vivas Consuelo" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/13012052?idApp=WGSE" "url" => "/02139111/0000001300000SC1/v0_201302051654/13012052/v0_201302051655/es/main.assets" ] "itemAnterior" => array:16 [ "pii" => "13012059" "issn" => "02139111" "estado" => "S300" "fechaPublicacion" => "1999-08-01" "documento" => "article" "crossmark" => 0 "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Gac Sanit. 1999;13 Supl Congr 1:9052" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1743 "formatos" => array:3 [ "EPUB" => 170 "HTML" => 1445 "PDF" => 128 ] ] "es" => array:6 [ "idiomaDefecto" => true "titulo" => "IMPACTO DE LA ENFERMEDAD NEUMOCÓCICA EN ANCIANOS" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "9052" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A Salazar Cifre" "autores" => array:1 [ 0 => array:2 [ "Iniciales" => "A" "apellidos" => "Salazar Cifre" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/13012059?idApp=WGSE" "url" => "/02139111/0000001300000SC1/v0_201302051654/13012059/v0_201302051655/es/main.assets" ] "en" => array:7 [ "idiomaDefecto" => true "titulo" => "GEOGRAPHIC VARIATIONS IN INVASIVE PNEUMOCOCCAL DISEASE AND PNEUMOCOCCAL VACCINATION IN WESTERN EUROPE" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "9053" ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "D Fedson" "autores" => array:1 [ 0 => array:2 [ "Iniciales" => "D" "apellidos" => "Fedson" ] ] ] ] "textoCompleto" => "GEOGRAPHIC VARIATIONS IN INVASIVE PNEUMOCOCCAL DISEASE AND PNEUMOCOCCAL VACCINATION IN WESTERN EUROPED.Fedson.Pasteur-Merieux-MSD.M.D. David Fedson. 8 rue Jonas Salk. 69367 Lyon Cedex 07. France.7E-Mail: fedson@fr.vaxiline.comBackground: Pneumococcal vaccine has not been widely used in western European countries, perhaps because of uncertainty about the incidence of pneumococcal pneumonia and limited evidence that vaccination prevents pneumococcal pneumonia in older adults. Recent increases in vaccine use in several countries have been accompanied by more information on the incidence of invasive pneumococcal disease and wider acceptance of retrospective studies showing that vaccination prevents invasive disease. Nonetheless, there are still large geographic variations among western European countries in the reported incidence of invasive disease and the use of the vaccine.Methods: The aims of this study were to review data on the reported incidence of invasive pneumococcal disease and pneumococcal vaccine use in western European countries in the 1990s. Information on disease incidence was obtained from published and unpublished reports. Data were also gathered on disease incidence in smaller geographic regions within three countries. Information was also obtained on the cumulative use of pneumococcal vaccine in each country during the 5-year period 1993-1997. Vaccine use was also documented for smaller regions in two countries. Information on vaccination recommendations and reimbursement in 1997 was also obtained.Findings: The reported incidence of invasive pneumococcal disease in western European countries varied from 6 to 27 cases per 100,000 persons of all ages and from 27 to 80 cases per 100,000 persons >65 years in age. In some countries the disease incidence appeared to have increased over the years. Larger (4- to 6-fold) variations in disease incidence were reported among smaller regions within three countries in individual years. During the 1993-1997 period, very large differences in pneumococcal vaccine use were observed between western European countries, between smaller regions within countries and between individual general practices. Although increased vaccine use was noted in several countries during this period, in 1997 pneumococcal vaccine remained little used throughout most of western Europe.Interpretation: Geographic variations in the reported incidence of invasive pneumococcal disease between and within western European countries probably reflect differences in surveillance and case ascertainment, rather than true differences or absolute increases in disease occurrence. In all countries, the annual incidence is probably >15-20 cases per 100,000 persons of all ages, and >50 cases per 100,000 persons >65 years in age. The large differences in vaccine use observed between and within countries demonstrate that implementation of pneumococcal vaccination throughout western Europe remains uneven. Understanding the reasons underlying the geographic variations in the incidence of invasive pneumococcal disease and the use of pneumococcal vaccine will help to ensure that increasing numbers of people benefit from this safe and effective vaccine." "tienePdf" => false ] "idiomaDefecto" => "en" "url" => "/02139111/0000001300000SC1/v0_201302051654/13012061/v0_201302051655/en/main.assets" "Apartado" => array:4 [ "identificador" => "835" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Sesión espontánea. La enfermedad neumocócica: problemática y prevención" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/13012061?idApp=WGSE"]

Gaceta Sanitaria

ISSN: 0213-9111

Gaceta Sanitaria es la revista científica y órgano de expresión de la Sociedad Española de Salud Pública y Administración Sanitaria (SESPAS).
Gaceta Sanitaria acepta para su publicación artículos en español e inglés. Es una revista Open Access (OA); todos sus artículos son accesibles libremente sin cargo para el usuario y se distribuyen con la licencia Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional

Call for papers: Special Issue on Health Economics

Convocatoria abierta y permanente para incorporar Editores/as asociados/as al Comité Editorial de Gaceta Sanitaria

Call for papers: Special Issue on Health Economics

Open and permanent call to incorporate Associate Editors to the Editorial Committee of Gaceta Sanitaria

Indexada en:

Web of Science (Science Citation Index, SCI, y Social Sciences Citation Index, SSCI), Medline/PubMed, Index Medicus, Scopus, Scielo, IBECS, Índice Médico Español, Toxline, Cancerlit, Aidsline, Cab Health, Bibliomed, Cuiden, Eventline y Healthstar

Respuestas rápidas

Nueva respuesta rápida:

Requisitos y consideraciones

Las respuestas rápidas tienen como objetivo permitir el debate sobre observaciones científicas y de opinión sobre trabajos publicados el último año.
Deben ser enviadas desde la página web correspondiente al artículo en cuestión (no a través del sistema general de envío de artículos).
Son moderadas antes de su publicación a discreción del equipo editorial de la revista, no obstante no son peer-reviewed.
Deben ser originales y no infringir los derechos propiedad de terceros.
Los/las autores/as perderán el derecho a borrar o editar el texto, una vez sea publicado. Asimismo, la revista se reserva el derecho de borrar o editar el texto a discreción.
Algunas respuestas rápidas podrían ser seleccionadas adicionalmente para su publicación como cartas en la revista, en este caso seguirán el proceso editorial correspondiente.
Las respuestas rápidas serán publicadas en la web de la revista en 1 semana aproximadamente, después del envío del texto por parte de los/as autores/as.
La extensión máxima será de 500 palabras. Se admitirá una tabla o figura y hasta 5 referencias bibliográficas.
Se comunicará a los/las autores/ras del artículo comentado la existencia de la carta y la posibilidad de respuesta.
Al enviar esta respuesta rápida los autores/as aceptan los requisitos descritos.